Barclays Maintains Overweight on Intellia Therapeutics, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Intellia Therapeutics (NASDAQ:NTLA) and raises the price target from $86 to $90.
August 07, 2023 | 3:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Intellia Therapeutics and raises the price target from $86 to $90, indicating a positive outlook for the stock.
The raised price target by Barclays indicates their belief in the company's potential for growth. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100